Header graphic for print
MoFo Tech A blog dedicated to information, trend spotting & analysis for science- & tech-based companies

Category Archives: Pharmaceuticals

Subscribe to Pharmaceuticals RSS Feed

For the Common Good

For-profits and nonprofits in life sciences team up Nonprofit groups are actively supporting research to solve tough medical challenges. Life sciences and pharma companies are eager to accelerate product development. Now, new business models are emerging to leverage the strengths of each. One example: the licensing partnership between Medicines360, a San Francisco-based nonprofit pharma company… Continue Reading

Biotech: Let’s Make a Deal

Scientific acumen is crucial—but so is an understanding of today’s deal market. The risks and costs of life sciences product development have become so high that few companies are willing to bear them on their own. As partnerships become vital, skill in dealmaking has become almost as vital as scientific acumen for today’s pharma and… Continue Reading

The End of “Pay For Delay”?

More brand-name drug companies have been paying their competitors to delay their efforts to bring generic versions of blockbuster pharmaceuticals to market. The Federal Trade Commission estimates there were 28 “reverse payment” agreements in 2011—twice the number in 2007—involving 25 different branded pharmaceuticals with annual U.S. sales of more than $9 billion. A string of… Continue Reading

Biosimilars: On a Different Path

Brand-new FDA guidelines have created a long-awaited shortcut for bringing biosimilars—cheaper versions of biologically derived pharmaceuticals—to the U.S. market. But the pathway won’t be nearly as straightforward as the one for generic versions of less complex, chemically based drugs that was created under the Hatch-Waxman Act in 1984. Unlike the Hatch-Waxman route, the biosimilar guidelines… Continue Reading